688 related articles for article (PubMed ID: 24882567)
1. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.
Kraehenmann R; Preller KH; Scheidegger M; Pokorny T; Bosch OG; Seifritz E; Vollenweider FX
Biol Psychiatry; 2015 Oct; 78(8):572-81. PubMed ID: 24882567
[TBL] [Abstract][Full Text] [Related]
2. Emotions and brain function are altered up to one month after a single high dose of psilocybin.
Barrett FS; Doss MK; Sepeda ND; Pekar JJ; Griffiths RR
Sci Rep; 2020 Feb; 10(1):2214. PubMed ID: 32042038
[TBL] [Abstract][Full Text] [Related]
3. Effects of serotonin 2A/1A receptor stimulation on social exclusion processing.
Preller KH; Pokorny T; Hock A; Kraehenmann R; Stämpfli P; Seifritz E; Scheidegger M; Vollenweider FX
Proc Natl Acad Sci U S A; 2016 May; 113(18):5119-24. PubMed ID: 27091970
[TBL] [Abstract][Full Text] [Related]
4. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors.
Kometer M; Schmidt A; Bachmann R; Studerus E; Seifritz E; Vollenweider FX
Biol Psychiatry; 2012 Dec; 72(11):898-906. PubMed ID: 22578254
[TBL] [Abstract][Full Text] [Related]
5. Lysergic Acid Diethylamide and Psilocybin Revisited.
Geyer MA
Biol Psychiatry; 2015 Oct; 78(8):516-8. PubMed ID: 26386624
[No Abstract] [Full Text] [Related]
6. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.
Pokorny T; Preller KH; Kraehenmann R; Vollenweider FX
Eur Neuropsychopharmacol; 2016 Apr; 26(4):756-66. PubMed ID: 26875114
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
Grob CS; Danforth AL; Chopra GS; Hagerty M; McKay CR; Halberstadt AL; Greer GR
Arch Gen Psychiatry; 2011 Jan; 68(1):71-8. PubMed ID: 20819978
[TBL] [Abstract][Full Text] [Related]
8. Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination.
Grimm O; Kraehenmann R; Preller KH; Seifritz E; Vollenweider FX
Eur Neuropsychopharmacol; 2018 Jun; 28(6):691-700. PubMed ID: 29703645
[TBL] [Abstract][Full Text] [Related]
9. The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity.
Kraehenmann R; Schmidt A; Friston K; Preller KH; Seifritz E; Vollenweider FX
Neuroimage Clin; 2016; 11():53-60. PubMed ID: 26909323
[TBL] [Abstract][Full Text] [Related]
10. Neural Mechanisms of Resting-State Networks and the Amygdala Underlying the Cognitive and Emotional Effects of Psilocybin.
Stoliker D; Novelli L; Vollenweider FX; Egan GF; Preller KH; Razi A
Biol Psychiatry; 2024 Jul; 96(1):57-66. PubMed ID: 38185235
[TBL] [Abstract][Full Text] [Related]
11. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
Griffiths RR; Johnson MW; Richards WA; Richards BD; McCann U; Jesse R
Psychopharmacology (Berl); 2011 Dec; 218(4):649-65. PubMed ID: 21674151
[TBL] [Abstract][Full Text] [Related]
12. The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability.
Carhart-Harris RL; Williams TM; Sessa B; Tyacke RJ; Rich AS; Feilding A; Nutt DJ
J Psychopharmacol; 2011 Nov; 25(11):1562-7. PubMed ID: 20395317
[TBL] [Abstract][Full Text] [Related]
13. Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study.
Marschall J; Fejer G; Lempe P; Prochazkova L; Kuchar M; Hajkova K; van Elk M
J Psychopharmacol; 2022 Jan; 36(1):97-113. PubMed ID: 34915762
[TBL] [Abstract][Full Text] [Related]
14. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.
Studerus E; Kometer M; Hasler F; Vollenweider FX
J Psychopharmacol; 2011 Nov; 25(11):1434-52. PubMed ID: 20855349
[TBL] [Abstract][Full Text] [Related]
15. Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations.
Kometer M; Pokorny T; Seifritz E; Volleinweider FX
Psychopharmacology (Berl); 2015 Oct; 232(19):3663-76. PubMed ID: 26231498
[TBL] [Abstract][Full Text] [Related]
16. Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.
Johnson MW; Sewell RA; Griffiths RR
Drug Alcohol Depend; 2012 Jun; 123(1-3):132-40. PubMed ID: 22129843
[TBL] [Abstract][Full Text] [Related]
17. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.
Griffiths RR; Richards WA; McCann U; Jesse R
Psychopharmacology (Berl); 2006 Aug; 187(3):268-83; discussion 284-92. PubMed ID: 16826400
[TBL] [Abstract][Full Text] [Related]
18. Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers.
Bravermanová A; Viktorinová M; Tylš F; Novák T; Androvičová R; Korčák J; Horáček J; Balíková M; Griškova-Bulanova I; Danielová D; Vlček P; Mohr P; Brunovský M; Koudelka V; Páleníček T
Psychopharmacology (Berl); 2018 Feb; 235(2):491-503. PubMed ID: 29302713
[TBL] [Abstract][Full Text] [Related]
19. Acute effects of heroin on negative emotional processing: relation of amygdala activity and stress-related responses.
Schmidt A; Borgwardt S; Gerber H; Wiesbeck GA; Schmid O; Riecher-Rössler A; Smieskova R; Lang UE; Walter M
Biol Psychiatry; 2014 Aug; 76(4):289-96. PubMed ID: 24314348
[TBL] [Abstract][Full Text] [Related]
20. Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan.
Carbonaro TM; Johnson MW; Griffiths RR
Psychopharmacology (Berl); 2020 Aug; 237(8):2293-2304. PubMed ID: 32500212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
